N-acetylcysteine augments adenovirus-mediated gene expression in human endothelial cells by enhancing transgene transcription and virus entry

Journal of Gene Medicine

Volumn 4, Issue 1, 2002, Pages 54-65

  Jornot, Lan ^a   Morris, M A ^a   Petersen, H ^a   Moix, I ^a   Rochat, T ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

lipoic acid; Coxsackie virus receptors; Gene therapy; Oxidants

Indexed keywords

ACETYLCYSTEINE; ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; BETA GALACTOSIDASE; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; THIOCTIC ACID; VIRUS DNA; CAR RECEPTOR; VIRUS RECEPTOR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOFLUOROMETRY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ADENOVIRUS; CELL CULTURE; GENE VECTOR; LACTOSE OPERON; PHYSIOLOGY; UMBILICAL VEIN; UPREGULATION; VASCULAR ENDOTHELIUM;

ADENOVIRIDAE; COXSACKIEVIRUS; RICE STRIPE VIRUS;

ACETYLCYSTEINE; ADENOVIRIDAE; BETA-GALACTOSIDASE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LAC OPERON; RECEPTORS, VIRUS; THIOCTIC ACID; TRANSCRIPTION, GENETIC; TRANSGENES; UMBILICAL VEINS; UP-REGULATION;

EID: 0036368638     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.232     Document Type: Article

References (34)

1. Christ M, Louis B, Stoeckel F, et al. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum Gene Ther 2000; 11 415-427.
2. Hemmi S, Geertsen R, Mezzacasa A, et al. The presence of human Coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363-2373.
3. Armentano D, Zabner J, Sacks C, et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71: 2408-2416.
4. Qin L, Ding Y, Pahud DR, et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression [see comments]. Hum Gene Ther 1997; 8: 2019-2029.
5. Clesham GJ, Browne H, Efstathiou S, et al. Enhancer stimulation unmasks latent gene transfer after adenovirus-mediated gene delivery into human vascular smooth muscle cells. Circ Res 1996; 79: 1188-1195.
6. Loser P, Jennings GS, Strauss M, et al. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
7. Christenson SD, Lund D, Ooboshi H, et al. Approaches to enhance expression after adenovirus-mediated gene transfer to the carotid artery. Endothelium 1999; 7: 75-82.
8. Bruening W, Giasson B, Mushynski W, et al. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res 1998; 26: 486-489.
9. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205-227.
10. Sen CK. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000; 36: 1-30.
11. Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
12. Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998; 72: 2022-2032.
13. Jornot L, Junod AF. Hyperoxia, unlike phorbol ester, induces glutathione peroxidase through a protein kinase C-independent mechanism. Biochem J 1997; 326: 117-123.
14. Bergelson JM. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol 1999; 57: 975-979.
15. Nemerow GR. Cell receptors involved in adenovirus entry. Virology 2000; 274: 1-4.
16. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev 1998; 3: 114-127.
17. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997; 29: 315-331.
18. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 1998; 55: 1747-1758.
19. 2 and TNFα. Differences between in vivo and in vitro effects. FEBS Lett 1997; 416: 381-386.
20. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70: 6831-6838.
21. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
22. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a Coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
23. McDonald D, Stockwin L, Matzow T, et al. Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cells. Gene Ther 1999; 6: 1512-1519.
24. Davison E, Kirby I, Elliott T, et al. The human HLA-A* 0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber. J Virol 1999; 73: 4513-4517.
25. Greber UF. Virus assembly and disassembly: the adenovirus cysteine protease as a trigger factor. Rev Med Virol 1998; 8: 213-222.
26. Greber UF, Webster P, Weber J, et al. The role of the adenovirus protease on virus entry into cells. EMBO J 1996; 15 1766-1777.
27. Haddad IY, Sorscher EJ, Garver RIJ, et al. Modulation of adenovirus-mediated gene transfer by nitric oxide [see comments]. Am J Respir Cell Mol Biol 1997; 16: 501-509.
28. Sanlioglu S, Engelhardt JF. Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways. Gene Ther 1999; 6: 1427-1437.
29. Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253-262.
30. Kasielski M, Nowak D. Long-term administration of N acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95: 448-456.
31. Gelband CH, Katovich MJ, Raizada MK. Current perspectives on the use of gene therapy for hypertension. Circ Res 2000; 87: 1118-1122.
32. Sinnaeve P, Varenne O, Collen D, et al. Gene therapy in the cardiovascular system: an update. Cardiovasc Res 1999; 44 498-506.
33. Sacco MG, Cato EM, Ceruti R, et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther 2001; 8: 67-70.
34. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001; 38: 177-192.